Summary
This phase II trial studies the effect of cabozantinib, nivolumab, and ipilimumab for the treatment of non-clear cell renal cell cancer (kidney cancer) that has spread to other places in the body (metastatic). Cabozantinib may stop the growth of tumor cells by blocking some of the enzymes needed for cell growth. Immunotherapy with monoclonal antibodies, such as nivolumab and ipilimumab, may help the body's immune system attack the tumor, and may interfere with the ability of tumor cells to grow and spread. The purpose of this trial is to assess whether cabozantinib, nivolumab, and ipilimumab in combination are safe and effective (how well the drug works) in slowing down the growth of kidney cancer.